Moreover, the BCR::ABL1 fusion gene, created by the t (9;22) (q34;q11) translocation, is detected in about 2% of pediatric ALL cases—less often than in adolescents and young adults—and has long been recognized as a marker of higher-risk disease under conventional therapies [25]. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.